Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation

Abroad (travel likely)RecruitingPHASE3

Conditions

Hepatocellular Carcinoma · Liver Transplantation

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Nanjing Drum tower hospital, Nanjing, Jiangsu, China
Contact: Study coordinator (Beicheng Sun, Phd,MD) · sunbc@nju.edu.cn · +8613776413940

Study leads

Beicheng Sun, PhD，MD
Study Chair
Nanjing University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC

Hepatocellular Carcinoma (HCC) · Radiotherapy, Adjuvant · Immune Checkpoint Inhibitor

Abroad (travel likely)RecruitingPHASE3

Beijing, China

Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE3

Nanchang, China · Chifeng, China

HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE3

Foshan, China · Guangzhou, China

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

Hepatocellular Carcinoma Non-resectable

Abroad (travel likely)RecruitingPHASE3

Guangzhou, China